Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 4/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359028 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL6939834 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5734713 | 0.97 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5734723 | 0.97 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL9166176 | 0.96 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL6938649 | 0.96 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL12958834 | 0.96 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL21710733 | 0.96 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL9173436 | 0.96 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5737339 | 0.96 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1110554-B1 | MEDICINAL COMPOSITIONS FOR TREATING EYE DISEASES | YAMASA CORP (JP) | 2006-03-08 | — | — | EP | claimed |
| US-6387889-B1 | REDUCING OCULAR TENSION | YAMASA CORPORATION (JP) | 2002-05-14 | — | — | US | claimed |
| EP-1110554-A1 | MEDICINAL COMPOSITIONS FOR TREATING EYE DISEASES | YAMASA CORPORATION (JP) | 2001-06-27 | — | — | EP | claimed |
| US-7189706-B2 | C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2007-03-13 | — | — | US | disclosed |
| US-7112574-B2 | found to be potent adenosine receptor agonists, in particular for the A2A receptor. | UNIVERSITEIT LEIDEN (NL) | 2006-09-26 | — | — | US | disclosed |
| EP-1368364-B1 | C2, 8-DISUBSTITUTED ADENOSINE DERIVATIVES AND THEIR DIFFERENT USES | UNIV LEIDEN (NL) | 2006-09-20 | — | — | EP | disclosed |
| US-7084127-B2 | C2,5′-disubstituted and N6, C2,5′-trisubstituted adenosine derivatives and their different uses | UNIVERSITEIT LEIDEN (NL) | 2006-08-01 | — | — | US | disclosed |
| EP-1110554-B1 | MEDICINAL COMPOSITIONS FOR TREATING EYE DISEASES | YAMASA CORP (JP) | 2006-03-08 | — | — | EP | disclosed |
| US-20040132686-A1 | C2,5'- disubstituted and N6, c2,5'- trisubstituted adenosine derivatives and their different uses | UNIVERSITEIT LEIDEN (NL) | 2004-07-08 | — | — | US | disclosed |
| US-20040127452-A1 | C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2004-07-01 | — | — | US | disclosed |
| US-20040116374-A1 | C2, 8-disubstituted adenosine derivatives and their different uses | UNIVERSITEIT LEIDEN (NL) | 2004-06-17 | — | — | US | disclosed |
| US-6387889-B1 | REDUCING OCULAR TENSION | YAMASA CORPORATION (JP) | 2002-05-14 | — | — | US | disclosed |
| EP-1110554-A1 | MEDICINAL COMPOSITIONS FOR TREATING EYE DISEASES | YAMASA CORPORATION (JP) | 2001-06-27 | — | — | EP | disclosed |
| US-5459254-A | Reversing the order of the amination and alkynylation steps | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1995-10-17 | — | — | US | disclosed |
| EP-0429681-B1 | INTERMEDIATE FOR 2-ALKYNYLADENOSINE SYNTHESIS, PRODUCTION OF SAID INTERMEDIATE, PRODUCTION OF 2-ALKYNYLADENOSINE FROM SAID INTERMEDIATE, AND STABLE 2-ALKYNYLADENOSINE DERIVATIVE | YAMASA SHOYU KK (JP) | 1995-09-06 | — | — | EP | disclosed |
| EP-0444196-B1 | AGENT FOR TREATMENT AND PROPHYLAXIS OF ISCHEMIC DISEASE OF HEART OR BRAIN | YAMASA SHOYU KK (JP) | 1994-06-08 | — | — | EP | disclosed |
| US-5283327-A | Synthetic intermediate for 2-alkynyladenosine; storage stability | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1994-02-01 | — | — | US | disclosed |
| US-5270304-A | Therapeutic 2-alkynyl adenosine agent for ischemic diseases of the heart or brain | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1993-12-14 | — | — | US | disclosed |
| EP-0444196-A1 | AGENT FOR TREATMENT AND PROPHYLAXIS OF ISCHEMIC DISEASE OF HEART OR BRAIN | Yamasa Shoyu Kabushiki Kaisha (JP) | 1991-09-04 | — | — | EP | disclosed |
| EP-0429681-A1 | INTERMEDIATE FOR 2-ALKYNYLADENOSINE SYNTHESIS, PRODUCTION OF SAID INTERMEDIATE, PRODUCTION OF 2-ALKYNYLADENOSINE FROM SAID INTERMEDIATE, AND STABLE 2-ALKYNYLADENOSINE DERIVATIVE | Yamasa Shoyu Kabushiki Kaisha (Yamasa Corporation) (JP) | 1991-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127452-A1 | C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA2B 4/4885 |
| US-20040132686-A1 | C2,5'- disubstituted and N6, c2,5'- trisubstituted adenosine derivatives and their different uses | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.